Depressive disorders in comorbidity with Multiple Sclerosis. Case study
Introduction Multiple Sclerosis is a neurodegenerative, demyelinating disease that affects the Central Nervous System. Except for motor dysfunction and sensory deficit, patients suffering from this disorder often have neuropsychiatric symptoms, such as: depressive mood, fatigue, and cognitive impai...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2023-03-01
|
| Series: | European Psychiatry |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823015900/type/journal_article |
| _version_ | 1797616056373608448 |
|---|---|
| author | E. Shaska |
| author_facet | E. Shaska |
| author_sort | E. Shaska |
| collection | DOAJ |
| description |
Introduction
Multiple Sclerosis is a neurodegenerative, demyelinating disease that affects the Central Nervous System. Except for motor dysfunction and sensory deficit, patients suffering from this disorder often have neuropsychiatric symptoms, such as: depressive mood, fatigue, and cognitive impairment. Depression is the most common mental disorder in Multiple Sclerosis, and the risk that MS patients develop depression during their entire life is >50%.
Objectives
Factors impacting on the development of depression
Methods
A regular, clinical study approach has been used on a 49-year old woman, who was diagnosed with depressive Disorder 2 years ago and then Multiple Sclerosis, as well as recent literature on depressive disorders in comorbidity with Multiple Sclerosis.
Results
The factors that considerably impact the development of depression are age, gender, insomnia, cognitive impairment, MS clinical picture, and immunotherapy treatment. Depression was diagnosed at the clinical interview, based on DSM-5 diagnosis criteria and Beck Inventory, whereas MS diagnosis was determined by neurological examination and head MRI. The patient was treated with tricyclic antidepressants, SSRIs, SNRIs, atypical antipsychotics for depression, and teriflunomide for MS. Depression has been recurrent, despite being regularly treated with psychotropic medications
Conclusions
Depressive disorders in comorbidity with multiple sclerosis are often undiagnosed and improperly treated. Many factors influence the development and progression of depression, as well as the Multiple Sclerosis clinical picture, above all. Early diagnosis and optimal treatment of them are essential to control the disease and improve the quality of life.
Disclosure of Interest
None Declared |
| first_indexed | 2024-03-11T07:35:46Z |
| format | Article |
| id | doaj.art-44642bc472664c4099be2e9f4aaa9979 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:35:46Z |
| publishDate | 2023-03-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-44642bc472664c4099be2e9f4aaa99792023-11-17T05:09:49ZengCambridge University PressEuropean Psychiatry0924-93381778-35852023-03-0166S755S75510.1192/j.eurpsy.2023.1590Depressive disorders in comorbidity with Multiple Sclerosis. Case studyE. Shaska0Acute Care Unit, Psychiatric Hospital “Ali Mihali” Vlore, Vlora, Albania Introduction Multiple Sclerosis is a neurodegenerative, demyelinating disease that affects the Central Nervous System. Except for motor dysfunction and sensory deficit, patients suffering from this disorder often have neuropsychiatric symptoms, such as: depressive mood, fatigue, and cognitive impairment. Depression is the most common mental disorder in Multiple Sclerosis, and the risk that MS patients develop depression during their entire life is >50%. Objectives Factors impacting on the development of depression Methods A regular, clinical study approach has been used on a 49-year old woman, who was diagnosed with depressive Disorder 2 years ago and then Multiple Sclerosis, as well as recent literature on depressive disorders in comorbidity with Multiple Sclerosis. Results The factors that considerably impact the development of depression are age, gender, insomnia, cognitive impairment, MS clinical picture, and immunotherapy treatment. Depression was diagnosed at the clinical interview, based on DSM-5 diagnosis criteria and Beck Inventory, whereas MS diagnosis was determined by neurological examination and head MRI. The patient was treated with tricyclic antidepressants, SSRIs, SNRIs, atypical antipsychotics for depression, and teriflunomide for MS. Depression has been recurrent, despite being regularly treated with psychotropic medications Conclusions Depressive disorders in comorbidity with multiple sclerosis are often undiagnosed and improperly treated. Many factors influence the development and progression of depression, as well as the Multiple Sclerosis clinical picture, above all. Early diagnosis and optimal treatment of them are essential to control the disease and improve the quality of life. Disclosure of Interest None Declaredhttps://www.cambridge.org/core/product/identifier/S0924933823015900/type/journal_article |
| spellingShingle | E. Shaska Depressive disorders in comorbidity with Multiple Sclerosis. Case study European Psychiatry |
| title | Depressive disorders in comorbidity with Multiple Sclerosis. Case study |
| title_full | Depressive disorders in comorbidity with Multiple Sclerosis. Case study |
| title_fullStr | Depressive disorders in comorbidity with Multiple Sclerosis. Case study |
| title_full_unstemmed | Depressive disorders in comorbidity with Multiple Sclerosis. Case study |
| title_short | Depressive disorders in comorbidity with Multiple Sclerosis. Case study |
| title_sort | depressive disorders in comorbidity with multiple sclerosis case study |
| url | https://www.cambridge.org/core/product/identifier/S0924933823015900/type/journal_article |
| work_keys_str_mv | AT eshaska depressivedisordersincomorbiditywithmultiplesclerosiscasestudy |